Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITR-251
- Development stage
- Phase 1
- Lead developer
- Iteria Biopharma
- Modality
- Small Molecules
01
Overview
ITR-251 is a small-molecule inhibitor of monoamine oxidase A (MAO-A) currently under development by Iteria Biopharma for the treatment of solid tumors. MAO-A is an enzyme traditionally known for its role in the central nervous system, but it has recently emerged as a potential target in oncology due to its role in promoting tumor cell proliferation and suppressing anti-tumor immunity within the tumor microenvironment. By inhibiting MAO-A, ITR-251 is designed to disrupt these pro-tumorigenic pathways and potentially enhance the immune system's ability to recognize and attack cancer cells. The program is currently in the IND-enabling or Phase 1 stage of clinical development.
02
Targets
Beyond the preview
Go deeper on ITR-251.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITR-251.